Compare · BMY vs PFE
BMY vs PFE
Side-by-side comparison of Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMY and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $142.77B, about 1.2x BMY ($124.04B).
- Over the past year, BMY is up 28.2% and PFE is up 2.4% - BMY leads by 25.8 points.
- PFE has been more active in the news (17 items in the past 4 weeks vs 7 for BMY).
- Both have 25 recent analyst ratings on file.
- Company
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Price
- $60.74+0.37%
- $25.05-0.36%
- Market cap
- $124.04B
- $142.77B
- 1M return
- +8.59%
- -3.84%
- 1Y return
- +28.21%
- +2.37%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 7
- 17
- Recent ratings
- 25
- 25
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest BMY
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
- SEC Form 4 filed by Director Yale Phyllis R
- SEC Form 4 filed by Director Samuels Theodore R. Ii
- SEC Form 4 filed by Director Rice Derica W
- SEC Form 4 filed by Director Mcmullen Michael R.
- SEC Form 4 filed by Director Arduini Peter J
- The Quest to Repair What Multiple Sclerosis Takes Away
- Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
- Bristol Myers Squibb Announces Dividend
- Director Haller Julia A exercised 20,460 shares at a strike of $53.76, increasing direct ownership by 150% to 34,079 units (SEC Form 4)
Latest PFE
- SEC Form 4 filed by Chairman & CEO Bourla Albert
- AM Best Affirms Credit Ratings of Blue Whale Re Ltd.
- SEC Form 4 filed by Chairman & CEO Bourla Albert
- U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- Pfizer downgraded by HSBC Securities with a new price target
- SEC Form 4 filed by Chairman & CEO Bourla Albert
- SEC Form 4 filed by Director Buckley Mortimer J
- SEC Form 4 filed by Director Echevarria Joseph
- SEC Form 4 filed by Director Narayen Shantanu
- SEC Form 4 filed by Director Smith James C